SCHEMBL196919

SCHEMBL196919

O=C(O)C(O)c1ccc(F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.62
MAPK1 P28482 1/20 0.62
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
NPSR1 Q6W5P4 2/20 0.43
BLM P54132 1/20 0.43
TSHR P16473 1/20 0.43
MME P08473 1/20 0.42
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
BCL2L1 Q07817 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196920 1.00 LMNA (0.62) LMNAMAPK1HDAC3HDAC4HDAC1
SCHEMBL4632807 1.00 LMNA (0.62) LMNAMAPK1HDAC3HDAC4HDAC1
Fluoride SCHEMBL28879249 0.98 LMNA (0.60) LMNAMAPK1HDAC3HDAC4HDAC1
SCHEMBL8997409 0.94 LMNA (0.56) LMNAMAPK1HDAC3HDAC4HDAC1
SCHEMBL275597 0.87 LMNA (0.79) LMNAMAPK1NPSR1BLMTSHR
SCHEMBL19735013 0.79 HDAC3 (0.45) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL11218186 0.79 HDAC3 (0.45) LMNAMAPK1HDAC3HDAC4HDAC1
SCHEMBL4092644 0.79 HDAC3 (0.45) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL531658 0.79 HDAC3 (0.45) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL28795451 0.79 HPGD (0.48) LMNAMAPK1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113355367-B Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2024-03-26 CN claimed
CN-116836462-A High-wear-resistance rubber composite material and preparation method and application thereof 青岛科技大学 2023-10-03 CN claimed
CN-111056890-B Method for preparing aryl ketone by free radical-free radical coupling reaction of ketoacid decarboxylation and fatty aldehyde decarbonylation based on iron catalysis 湘潭大学 2022-10-14 CN claimed
US-20220325035-A1 POLYESTER, POLYESTERAMIDE, AND POLYAMIDE COMPOSITIONS IYER ANANTH V (US) 2022-10-13 US claimed
CN-113355299-B Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2022-05-24 CN claimed
CN-113355367-A Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2021-09-07 CN claimed
CN-113355299-A Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2021-09-07 CN claimed
CN-108410831-B Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid 浙江工业大学 2021-07-27 CN claimed
JP-11152247-A None JP disclosed
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-04-09 US disclosed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 EP disclosed
EP-3609891-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-02-11 EP disclosed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-3898581-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2025-08-27 EP disclosed
EP-0459455-A2 Process for producing optically active alpha-hydroxyesters CHISSO CORPORATION (JP) 1991-12-04 EP disclosed
US-4297489-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1981-10-27 US disclosed
US-4218380-A OXIDATION OF THE A-HYDROXY-ARYLACETIC ACID BAYER AKTIENGESELLSCHAFT (DE) 1980-08-19 US disclosed
US-4172196-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1979-10-23 US disclosed
US-4112228-A BACTERICIDES BRISTOL-MYERS COMPANY (US) 1978-09-05 US disclosed
US-3985738-A ANTIBACTERIAL AGENTS BRISTOL-MYERS COMPANY (US) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B LMNA 471/4885MAPK1 1302/4885HDAC3 532/4885
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS KCNH2, KCNH3, KCNH1 LMNA 1059/4885MAPK1 3023/4885HDAC3 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.